Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Follow-Up Questions
Who is the CEO of Fortress Biotech Inc?
Dr. Adm. Lindsay Rosenwald is the Executive Chairman of the Board of Fortress Biotech Inc, joining the firm since 2009.
What is the price performance of FBIOP stock?
The current price of FBIOP is $9.01, it has increased 0.08% in the last trading day.
What are the primary business themes or industries for Fortress Biotech Inc?
Fortress Biotech Inc belongs to Biotechnology industry and the sector is Health Care
What is Fortress Biotech Inc market cap?
Fortress Biotech Inc's current market cap is $268.2M
Is Fortress Biotech Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Fortress Biotech Inc, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell
